Plain-English translation of NCT07062263 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Biliary Tract Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining with works better than alone for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder) that has a specific genetic marker called HER2. is a targeted medication that attaches to HER2 and helps the immune system fight cancer cells. About 220 people will participate to see if this combination treatment helps patients live longer and keep their cancer from growing.
Biliary tract cancers are aggressive and difficult to treat, and standard alone only helps for a limited time. Early research suggests that this medication may improve outcomes for patients whose cancers have the HER2 marker, but we need a larger study to confirm whether it truly makes a meaningful difference.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either alone or plus . Both groups receive drugs (gemcitabine and cisplatin, with or without another drug called nab-paclitaxel) given intravenously every three weeks. If you are in the treatment group, you will also receive infusions on the same schedule. You will continue treatment until your cancer stops responding, you experience unacceptable side effects, or you choose to stop. You will have regular blood tests, imaging scans, and clinic visits to monitor how you are responding and to manage any side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
India